Navigating the ACCESS & TEMPO Models: A Direct Dialogue with CMMI & FDA Leaders

Navigating the ACCESS & TEMPO Models: A Direct Dialogue with CMMI & FDA Leaders

Watch AdvaMed® for an exclusive, member-only webinar as we delve into newly released details of the CMS ACCESS & FDA TEMPO Models. Featuring a direct perspective from senior CMS & FDA officials, this session will explore technical details of Model performance metrics and payment and regulatory pathways and provide an in-depth exploration of how these models aim to reshape access to new technologies for Medicare beneficiaries.

This unique opportunity to engage directly with CMS & FDA leaders and gain the insights your organization needs to assess the ACCESS & TEMPO Models and the Request for Applications, which closes April 1.

Air Date: Friday, March 6, 2026

Hear From:

Jacob Schiff Chief AI & Technology Officer CMS Innovation Center, Centers for Medicare & Medicaid Services

Courtney Lias Director, Office of In Vitro Diagnostic Devices, FDA

Key Takeaways:

• ACCESS & TEMPO Model Overview – Gain a comprehensive understanding of the newly released CMS ACCESS & FDA TEMPO Models and its implications for the medical technology industry.
• Performance Metrics & Payment Pathways – Explore technical details of how the model measures performance and structures payment for participating organizations.
• Impact on Medicare Beneficiaries – Understand how the ACCESS & TEMPO Models aims to reshape access to new technologies for Medicare beneficiaries.
• Request for Applications (RFA) Guidance – Learn what your organization needs to know ahead of the April 1 RFA closing date.
• Direct CMS & FDA Dialogue – Engage in a rare, direct conversation with senior CMS Innovation Center & FDA leaders.

WATCH NOW

Who Should Watch?

• In-house Payment, Coverage, and Reimbursement executives and personnel
• In-house legal counsel and compliance officers in the MedTech industry
• Executives and decision-makers in medical technology companies
• Government affairs and policy teams

This is a must-see session for MedTech professionals looking to understand the ACCESS & TEMPO Models, evaluate participation opportunities, and engage directly with CMS & FDA leaders before the April 1 RFA deadline.

This is a members-only event. Space is limited.

Speakers

Bobby Patrick, Senior Vice President, Government Affairs, AdvaMed
(Moderator)

Bobby Patrick leads AdvaMed’s state affairs work and partnerships with external stakeholders, including state biotech trade associations and patient advocacy groups. Previously, Bobby served as the vice president of strategic growth and policy at the Medical Alley Association, a Minnesota-based state healthcare trade association, where he led the state and federal advocacy efforts, as well as membership growth and retention.

Jacob Schiff Chief AI & Technology Officer CMS Innovation Center, Centers for Medicare & Medicaid Services

Jacob is Chief AI & Technology Officer at the CMS Innovation Center. He focuses on payment policy to enable the effective adoption of AI and technology across the healthcare system, including initiatives like CMS’ recently announced ACCESS Model. Prior to joining CMS, Jacob co-founded and led Anomaly, a venture-backed startup streamlining the health insurance billing and payment process, and worked at Redesign Health, Flatiron Health and Google. Jacob has a B.A. from the University of Pennsylvania and MBA from Stanford University.

Courtney Lias Director, Office of In Vitro Diagnostic Devices, FDA

Courtney H. Lias, Ph.D. – Dr. Lias studied at the Johns Hopkins University School of Medicine where she received her Ph.D. in Biochemistry, Cellular, and Molecular Biology.  Currently, Dr. Lias is the Director of FDA’s Office of In Vitro Diagnostic Devices. During her FDA career of over two decades, she has led efforts to promote development of new therapeutic and diagnostic devices, including devices for diabetes, genetic testing, infectious disease, and drug dosing and monitoring. In 2017, Dr. Lias received the Samuel J. Heyman Service to America Medal in Management Excellence. This honor was awarded for work promoting the efficient development and approval of the first automated insulin dosing system